Interactions Between Anti-Vegf Therapy and Antitumor Immunity as a Potential Therapeutic Strategy in Colorectal Cancer

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064190%3A_____%2F19%3AN0000108" target="_blank" >RIV/00064190:_____/19:N0000108 - isvavai.cz</a>

Alternative codes found

RIV/00216208:11110/19:10401445 RIV/00216208:11150/19:10401445 RIV/00179906:_____/19:10401445

Result on the web

<a href="https://actamedica.lfhk.cuni.cz/media/pdf/18059694.2019.129.pdf" target="_blank" >https://actamedica.lfhk.cuni.cz/media/pdf/18059694.2019.129.pdf</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.14712/18059694.2019.129" target="_blank" >10.14712/18059694.2019.129</a>

Result language

angličtina

Original language name

Interactions Between Anti-Vegf Therapy and Antitumor Immunity as a Potential Therapeutic Strategy in Colorectal Cancer

Original language description

There is a growing corpus of evidence indicating that anti-VEGF therapy may normalize the abnormal tumor vasculature with the potential to re-program the tumor immune microenvironment to a more immunosupportive profile. Tumor vessel normalization increases tumor perfusion, and, consequently, oxygen and nutrient supply, and thus can be assumed to improve the general response to anticancer immunotherapy. The increased antitumor immunity responses seen following anti-VEGF therapy may also be associated with the inhibition of the immunosuppressive action deployed by VEGF on effector T cells. Bearing in mind the recent advances of combination immunotherapy, combinations of anti-VEGF therapy with immune checkpoint inhibitors now appear to represent an attractive strategy. Key to the successful implementation of a combination strategy for treating cancer is understanding the interaction of these two therapeutic interventions, particularly in regards to appropriate reprogramming of the tumor immune microenvironment to improve antitumor immunity.

Czech name

—

Czech description

—

Type

J_SC - Article in a specialist periodical, which is included in the SCOPUS database

CEP classification

—

OECD FORD branch

30204 - Oncology

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2019

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Acta medica

ISSN

1211-4286

e-ISSN

—

Volume of the periodical

62

Issue of the periodical within the volume

3

Country of publishing house

CZ - CZECH REPUBLIC

Number of pages

4

Pages from-to

127-130

UT code for WoS article

—

EID of the result in the Scopus database

2-s2.0-85074307558